FY2017 Earnings Estimate for Endo International plc – Issued By Leerink Swann (ENDP)

Endo International plc – (NASDAQ:ENDP) (TSE:ENL) – Research analysts at Leerink Swann issued their FY2017 EPS estimates for shares of Endo International in a research note issued on Tuesday. Leerink Swann analyst A. Fadia anticipates that the company will post earnings per share of $3.65 for the year. Leerink Swann currently has a “Outperform” rating and a $12.00 target price on the stock. Leerink Swann also issued estimates for Endo International’s Q4 2017 earnings at $0.57 EPS, Q1 2018 earnings at $0.72 EPS, Q2 2018 earnings at $0.79 EPS, FY2018 earnings at $3.02 EPS, FY2019 earnings at $3.20 EPS, FY2020 earnings at $2.92 EPS and FY2021 earnings at $2.73 EPS.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. Endo International’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.01 EPS.

ENDP has been the subject of several other research reports. Zacks Investment Research upgraded Endo International from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a report on Wednesday, October 11th. Mizuho reiterated a “buy” rating and issued a $14.00 price objective (down previously from $19.00) on shares of Endo International in a report on Tuesday, September 12th. Royal Bank of Canada dropped their price objective on Endo International from $9.00 to $8.00 and set a “sector perform” rating for the company in a report on Friday, November 10th. Goldman Sachs Group initiated coverage on Endo International in a report on Thursday, September 28th. They issued a “sell” rating and a $7.00 price objective for the company. Finally, ValuEngine upgraded Endo International from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $11.27.

Shares of Endo International (NASDAQ ENDP) opened at $8.73 on Friday. Endo International has a fifty-two week low of $5.77 and a fifty-two week high of $17.63. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. The firm has a market capitalization of $1,978.56, a P/E ratio of -0.39, a price-to-earnings-growth ratio of 2.99 and a beta of 0.59.

Several large investors have recently made changes to their positions in ENDP. Sivik Global Healthcare LLC bought a new position in shares of Endo International in the 2nd quarter worth approximately $2,793,000. Diamond Hill Capital Management Inc. increased its position in Endo International by 46.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock valued at $6,138,000 after buying an additional 228,426 shares in the last quarter. River & Mercantile Asset Management LLP increased its position in Endo International by 116.3% during the 3rd quarter. River & Mercantile Asset Management LLP now owns 358,540 shares of the company’s stock valued at $3,071,000 after buying an additional 192,790 shares in the last quarter. Van ECK Associates Corp increased its position in Endo International by 67.1% during the 3rd quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock valued at $2,921,000 after buying an additional 136,873 shares in the last quarter. Finally, Quantitative Investment Management LLC bought a new position in Endo International during the 2nd quarter valued at approximately $1,344,000. 93.06% of the stock is owned by hedge funds and other institutional investors.

WARNING: “FY2017 Earnings Estimate for Endo International plc – Issued By Leerink Swann (ENDP)” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/01/05/fy2017-earnings-estimate-for-endo-international-plc-issued-by-leerink-swann-endp.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply